MedPath

Impact of Milk Polar Lipids on Lipids Digestion, Absorption and Metabolism

Not Applicable
Completed
Conditions
Cardiometabolic Risk
Interventions
Other: Cheese n°2- cheese n°3 - cheese n°1
Other: Cheese n°1- cheese n°2 - cheese n°3
Other: Cheese n°1- cheese n°3 - cheese n°2
Other: Cheese n°3 - cheese n°1- cheese n°2
Other: Cheese n°3- cheese n°2 - cheese n°1
Other: cheese n°2 - cheese n°1- cheese n°3
Registration Number
NCT02146339
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

Polar lipids have a specific chemical structure: they are an essential component of human cell membranes, play a major role in the nervous system and also influence the metabolic pathways including the cholesterol metabolism.

Polar lipids are used in food-processing industry for their emulsification properties. The most famous emulsifier is soya lecithin but milk also naturally contains natural emulsifiers such as polar lipids. Milk polar lipids are rich in sphingomyelin and they may have beneficial effects on lipid metabolism in the context of metabolic diseases of nutritional origin.

The purpose of this research is to study the variation of sphingomyelin content at the ileum's end after the consumption of different doses of milk polar lipids, and consequences on the intestinal absorption and metabolism of fatty acids and cholesterol.

The subjects will be taking three different test meals varying by their milk polar lipids content.

It is a bi-centric study with a centre in LYON (Centre de Recherche en Nutrition Humaine Rhône-Alpes) and CLERMONT-FERRAND (Centre de Recherche en Nutrition Humaine Auvergne).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
4
Inclusion Criteria
  • Men and women aged between 18 and 75 years
  • Having undergone a temporary or permanent ileostomy,
  • Considered to have well-functioning ileostomy
  • Normal (or not clinically significant) lipid parameters
Exclusion Criteria
  • Ileostomy due to an ongoing digestive cancer
  • Ileostomy due to a Chrohn's disease
  • Dairy products allergy or intolerance
  • Medication that could interfere with lipid metabolism

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
3g-5g milk polar lipid fortified-unfortified cheese productCheese n°2- cheese n°3 - cheese n°1Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
Unfortified-3g-5g milk polar lipid fortified cheese productCheese n°1- cheese n°2 - cheese n°3Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
Unfortified-5g-3g milk polar lipid fortified cheese productCheese n°1- cheese n°3 - cheese n°2Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
5g-unfortified-3g milk polar lipid fortified cheese productCheese n°3 - cheese n°1- cheese n°2Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
5g-3g milk polar lipid fortified-unfortified cheese productCheese n°3- cheese n°2 - cheese n°1Each subject will receive a single dose of each cheese product (100 g) containing no or 3g or 5g of milk polar lipids, 300 mg of \[1,1,1\]-13C-triolein and 45 mg of 2H6-cholesterol. The wash-out period is four weeks.
3g-Unfortified-5g milk polar lipid fortified cheese productcheese n°2 - cheese n°1- cheese n°3Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks. Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product
Primary Outcome Measures
NameTimeMethod
Ileal sphingomyelin outputup to Day 63

The total sphingomyelin output will be measured in the ileostomy fluids over 8 hours after the consumption of the 3 different test meals.

Secondary Outcome Measures
NameTimeMethod
Plasma lipids and isotopic tracersA least Day 7, Day 35 and Day 63

Plasma lipids and isotopic tracers will be measured after the consumption of the 3 different test meals. Fasting and postprandial measurements over 8 hours depending on parameters.

Energy expenditure and substrate oxidation with indirect calorimetryAt least Day7, Day 35 and Day 63

Energy metabolism and 13CO2 will be measured after the consumption of the 3 different test meals. Fasting and during all the postprandial period (8 h).

Plasma glucose and insulinAt least Day 7, Day 35 and Day 63

Plasma glucose and insulin will be measured after the consumption of the 3 different test meals. Fasting and postprandial measurements over 8 hours.

Trial Locations

Locations (2)

Centre de recherche en Nutrition Humaine-Auvergne -Unité d'Exploration Nutritionnelle

🇫🇷

Clermont-ferrand, France

Centre de Recherche en Nutrition Humaine Rhône-Alpes

🇫🇷

Lyon, France

© Copyright 2025. All Rights Reserved by MedPath